Abbisko-B (02256): Subsidiary presents preclinical research results of novel selective CDK4 inhibitor ABSK192 as monotherapy and in combination therapy at the 2026 ENA Conference
Zhitong Finance APP News, Abbisko-B (02256) announced that its subsidiary Shanghai Abbisko Biopharmaceutical Technology Co., Ltd. (Abbisko Therapeutics) announced that the preclinical research results of its independently developed novel selective CDK4 inhibitor ABSK192 were presented in poster form at the 38th EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium 2026 (2026 ENA Meeting). This study was selected for the Late-Breaking Abstracts (LBA) program, and Dr. Zhang Nannan, Senior Director of Translational Medicine and Biomarker Research at Abbisko Therapeutics, presented on-site the single-agent activity and broad combination therapy potential of ABSK192 in HR+/HER2- breast cancer models.
Latest
5 m ago

